The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
c-erbB-2 Is of Independent Prognostic Relevance in Gastric Cancer and Is Associated With the Expression of Tumor-Associated Protease Systems
Abstract
PURPOSE: The c-erbB-2 gene (encoding the protein p185) is overexpressed in diverse human cancers and has been implicated to be of prognostic value in gastric cancer. Recent studies suggest a role of p185 in tumor progression by specifically promoting the invasive capacity of tumor cells. Therefore, the present study was conducted with the following three objectives: (1) to support the prognostic value of c-erbB-2 in gastric cancer in a large prospective series using a monoclonal antibody and a highly sensitive immunohistochemical method; (2) to determine the association of c-erbB-2 expression with the expression of invasion-related genes; and (3) to perform the first overall multivariate analysis including c-erbB-2 and the invasion-related tumor-associated protease systems. PATIENTS AND METHODS: In a consecutive prospective series of 203 gastric cancer patients (median follow-up, 42 months), expression of c-erbB-2 and a panel of tumor-associated proteases and inhibitors by tumor cells were evaluated semiquantitatively (score 0 to 3) and analyzed for correlation (χ 2 test, Bonferroni-corrected). Kaplan-Meier survival analysis and multivariate Cox analysis were performed to determine the relative prognostic impact of c-erbB-2 and the invasion-related parameters. RESULTS: Kaplan-Meier analysis (log-rank statistics) revealed a significant association of increasing expression of c-erbB-2 with shorter disease-free (P = .0023) and overall survival (P = .0160). High amounts of p185 were significantly associated with a high expression of urokinase-type plasminogen activator (uPA) (P < .010), uPA-receptor (P = .030), type-1 plasminogen activator inhibitor (PAI) (P < .010), type-2 PAI (P = .021), cathepsin D (P = .036), matrix metalloproteinase-2 (P = .024), α-1-antichymotrypsin (P = .025), and α-2-macroglobulin (P = .017). Multivariate analysis considering these proteases/protease inhibitors, in addition to α-1-antitrypsin, tissue plasminogen activator, plasminogen, α-2-antiplasmin, and antithrombin III, and established prognostic parameters revealed that, in addition to surgical curability, pT stage, pN stage, and PAI-1, c-erbB-2 is an independent prognostic factor for overall survival of curatively resected patients (n = 139; P = .049; relative risk, 1.54; 95% confidence interval, 1.08 to 1.67) and all patients (P = .028; relative risk 1.33; 95% CI, 1.28 to 1.38). CONCLUSION: c-erbB-2 is confirmed as a new independent, functional prognostic parameter for overall survival in gastric cancer, even when a panel of invasion-related factors, including the strong prognostic parameter PAI-1, are considered. The significant correlation of p185 with several tumor-associated proteases supports the hypothesis that c-erbB-2 is a promoter of invasion and metastasis. This strongly suggests that c-erbB-2 may be a promising target for anti-invasive therapy in gastric cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Plasminogen Activators, Tissue Degradation, and Cancer
(1985) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60028-7 · Cited by 2,535
Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor
Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N., Miyajima, N., Saito, T., & Toyoshima, K. (1986) · Nature · doi:10.1038/319230a0 · Cited by 1,204
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Baselga, J. M., Norton, L., Albanell, J., Kim, Y. M., & Mendelsohn, J. M. (1998) · PubMed · Cited by 996
The biology of erbB-2/nue/HER-2 and its role in cancer
Hynes, N. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90012-4 · Cited by 971
Neu-Protein Overexpression in Breast Cancer
van de Vijver, M. J., Peterse, J. L., Mooi, W. J., Wisman, P., Lomans, J., Dalesio, O., & Nusse, R. (1988) · New England Journal of Medicine · doi:10.1056/nejm198811103191902 · Cited by 860
(1986) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60034-2 · Cited by 800
Akiyama, T., Sudo, C., Ogawara, H., Toyoshima, K., & Yamamoto, T. (1986) · Science · doi:10.1126/science.3012781 · Cited by 796
Berger, M. S., Locher, G. W., Saurer, S., Gullick, W. J., Waterfield, M. D., Groner, B., & Hynes, N. E. (1988) · PubMed · Cited by 611
Nakajima, M., Sawada, H., Yamada, Y., Watanabe, A., Tatsumi, M., Yamashita, J., Matsuda, M., Sakaguchi, T., Hirao, T., & Nakano, H. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990501)85:9%3c1894::aid-cncr3%3e3.0.co;2-j · Cited by 494
Blasi, F. (1993) · BioEssays · doi:10.1002/bies.950150206 · Cited by 395
AMPLIFICATION OF c-erbB-2 ONCOGENE IN HUMAN ADENOCARCINOMAS IN VIVO
Yokota, J., Toyoshima, K., Sugimura, T., Yamamoto, T., Terada, M., Battifora, H., & Cline, M. (1986) · The Lancet · doi:10.1016/s0140-6736(86)91782-4 · Cited by 392
Yonemura, Y., Ninomiya, I., Yamaguchi, A., Fushida, S., Kimura, H., Ohoyama, S., Miyazaki, I., Endou, Y., Tanaka, M., & Sasaki, T. (1991) · PubMed · Cited by 375
Jänicke, F., Schmitt, M., Pache, L., Ulm, K., Harbeck, N., Höfler, H., & Graeff, H. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf01833260 · Cited by 355
Fukushige, S., Matsubara, K., Yoshida, M., Sasaki, M., Suzuki, T., Semba, K., Toyoshima, K., & Yamamoto, T. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.3.955 · Cited by 324
Involvement of pp60c-src with two major signaling pathways in human breast cancer.
Luttrell, D. K., Lee, A., Lansing, T. J., Crosby, R. M., Jung, K. D., Willard, D., Luther, M., Rodriguez, M., Berman, J., & Gilmer, T. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.1.83 · Cited by 271
Tan, M., Yao, J., & Yu, D. (1997) · PubMed · Cited by 261
Satoh, T., Endo, M., Nakafuku, M., Akiyama, T., Yamamoto, T., & Kaziro, Y. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.20.7926 · Cited by 257
Heiss, M. M., Allgayer, H., Gruetzner, K. U., Funke, I., Babic, R., Jauch, K.-W., & Schildberg, F. W. (1995) · Nature Medicine · doi:10.1038/nm1095-1035 · Cited by 252
Self-citationIn vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion.
Ossowski, L., Clunie, G., Masucci, M. T., & Blasi, F. (1991) · The Journal of cell biology · doi:10.1083/jcb.115.4.1107 · Cited by 206
Oncogenic Activation of p185neu Stimulates Tyrosine Phosphorylation In Vivo
Stern, D. F., Kamps, M. P., & Cao, H. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.9.3969-3973.1988 · Cited by 147
Age dependence of ischaemic heart syndromes and the contribution of haemostatic deviations
Maseri, A., Biasucci, L. M., & Andreotti, F. (1992) · Fibrinolysis and Proteolysis · doi:10.1016/0268-9499(92)90003-z · Cited by 141
ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix.
Mitra, A., Murty, V. V. V. S., Pratap, M., Sodhani, P., & Chaganti, R. S. K. (1994) · PubMed · Cited by 122
Heiss, M. M., Babic, R., Allgayer, H., Gruetzner, K. U., Jauch, K. W., Loehrs, U., & Schildberg, F. W. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.8.2084 · Cited by 112
Self-citationPeles, E., Lamprecht, R., Ben-Levy, R., Tzahar, E., & Yarden, Y. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49834-7 · Cited by 87
Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells
Sasano, H., Date, F., Imatani, A., Asaki, S., & Nagura, H. (1993) · Human Pathology · doi:10.1016/0046-8177(93)90236-a · Cited by 83
Sistonen, L., Hölttä, E., Lehväslaiho, H., Lehtola, L., & Alitalo, K. K. (1989) · The Journal of Cell Biology · doi:10.1083/jcb.109.5.1911 · Cited by 80
Allgayer, H., Babic, R., Grützner, K. U., Beyer, B. C. M., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (1998) · Clinical & Experimental Metastasis · doi:10.1023/a:1006564002679 · Cited by 70
Self-citationAllgayer, H., Wang, H., Wang, Y., Heiss, M. M., Bauer, R., Nyormoi, O., & Boyd, D. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.8.4702 · Cited by 41
Self-citationAn immunohistochemical assessment of cathepsin D in gastric carcinoma
Allgayer, H., Babic, R., Gr�tzner, K. U., Beyer, B. C. M., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (1997) · Cancer · Cited by 35
Self-citationHeiss, M. M., Babic, R., Allgayer, H., Gruetzner, K. U., Jauch, K.-W., Loehrs, U., & Schildberg, F. W. (1996) · European Journal of Surgical Oncology · doi:10.1016/s0748-7983(96)91649-2 · Cited by 27
Self-citation
Cited by
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Assessment of a HER2 scoring system for gastric cancer: results from a validation study
Hofmann, M., Stoss, O., Shi, D., Büttner, R., Van De Vijver, M., Kim, W., Ochiai, A., Rüschoff, J., & Henkel, T. (2008) · Histopathology · doi:10.1111/j.1365-2559.2008.03028.x · Cited by 1,187
HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
Gravalos, C., & Jimeno, A. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn169 · Cited by 1,184
Gastric Adenocarcinoma: Review and Considerations for Future Directions
Dicken, B. J., Bigam, D. L., Cass, C., Mackey, J. R., Joy, A. A., & Hamilton, S. M. (2005) · Annals of Surgery · doi:10.1097/01.sla.0000149300.28588.23 · Cited by 691
Hecht, J. R., Bang, Y.-J., Qin, S. K., Chung, H. C., Xu, J. M., Park, J. O., Jeziorski, K., Shparyk, Y., Hoff, P. M., Sobrero, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6598 · Cited by 624
Metadata
- Authors
- Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2000-06-11
- Volume
- 18
- Issue
- 11
- Pages
- 2201-2209
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1807105923
- Cited by
- 276
- References
- 38
- FWCI
- 9.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.